Estrogens, conjugated
As of the edition of 20 October 2026, Estrogens, conjugated is a drug: marketed, first approved in 1963 (CA); acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Unknown
- Brand name
- Premarin
- First approved
- 31 December 1963 (CA)
- Approvals on record
- 29 in 3 regions
- Holder of the most recent approval
- Pfizer; 5 holders in all
- Registered trials
- 49, 8 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Cancer; Nutrition and metabolism; Skin and connective tissue; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 5 | 0 | 1 |
| Phase 1 | 12 | 10 | 0 | 2 |
| Phase 2 | 12 | 10 | 1 | 1 |
| Phase 3 | 10 | 7 | 0 | 3 |
| Phase 4 | 8 | 6 | 0 | 1 |
| All trials | 49 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1963 to now |
| Pfizer | Applicant, Acquired holder, Later holder and Lead sponsor of trials | 1994 to now |